New drug cocktail aims to improve multiple myeloma treatment before and after stem cell transplant
NCT ID NCT03896737
First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether adding the drug daratumumab to a standard chemotherapy combination (bortezomib, cyclophosphamide, and dexamethasone) works better than the current standard (bortezomib, thalidomide, and dexamethasone) for newly diagnosed multiple myeloma patients aged 18 to 65 who are eligible for a stem cell transplant. The study compares these two approaches as initial treatment and as consolidation after transplant, followed by maintenance therapy with either ixazomib alone or ixazomib plus daratumumab. The goal is to see which combination delays disease progression longer and achieves deeper remission.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- daratumumab, bortezomib, cyclophosphamide, dexamethasone, thalidomide, ixazomib
- What this could lead to
- If successful, this could lead to a more effective and safer treatment regimen for younger patients with newly diagnosed multiple myeloma, potentially improving long-term disease control.
- What could go wrong
- This is a phase 2 trial, so results are preliminary. The combination may cause significant side effects, and the benefit over current standard therapy is not yet proven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
A.O. Papa Giovanni XXIII
Bergamo, Italy
-
A.O. Spedali Civili di brescia
Brescia, Italy
-
A.O. di Perugia-Ospedale S. Maria della Misericordia
Perugia, Italy
-
A.O.U. Maggiore della Carità di Novara
Novara, 28100, Italy
-
A.O.U. Ospedali Riuniti Umberto I - G.M. Lancisi - G. Salesi di Ancona
Ancona, Italy
-
A.O.U. Policlinico San Martino
Genova, Italy
-
A.O.U. Policlinico Vittorio Emanuele di Catania
Catania, Italy
-
AOU Città della Salute e della Scienza di Torino
Torino, Italy
-
Arcispedale S. Maria Nuova
Reggio Emilia, Italy
-
Az. Osp. S. Maria
Terni, Italy
-
Dipartimento Medicina Clinica e Sperimentale - AO di Padova
Padova, Italy
-
General Hospital of Athens "Alexandra"
Athens, 115 28, Greece
-
General Hospital of Athens 'Evangelismos
Athens, Greece
-
General University Hospital (VFN)-Internal Medicine, Hematology Clinic
Prague, Czechia
-
Hradec Kralove-University Hospital Hradec Kralove
Hradec Králové, Czechia
-
I.R.C.C.S. Ospedale Casa Sollievo della Sofferenza
San Giovanni Rotondo, Italy
-
Ospedale Niguarda
Milan, Italy
-
Policlinico S. Matteo Fondazione IRCCS
Pavia, Italy
-
Policlinico S. Orsola
Bologna, Italy
-
University General Hospital of Patras
Pátrai, Greece
-
University Hospital Olomouc
Olomouc, Czechia
-
University Hospital Ostrava
Ostrava, 708 52, Czechia
-
University Hospital Ostrava
Ostrava, Czechia
-
University Hospital Plzen
Pilsen, Czechia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a gentler chemo-radiation combo make stem cell transplants safer for blood cancers?
- Can a cancer drug reboot the immune system after a stem cell transplant?
- A One-Shot gene therapy could take on incurable blood cancer
- New PET tracer could sharpen diagnosis of blood cancers
- Web tool aims to empower rare cancer patients in genomic choices
- Diabetes drug metformin could boost myeloma treatment